Hi-Tech Pharmacal Co Inc (HITK.OQ)

HITK.OQ on NASDAQ Stock Exchange Global Select Market

43.50USD
15 Apr 2014
Price Change (% chg)

$0.16 (+0.37%)
Prev Close
$43.34
Open
$43.48
Day's High
$43.51
Day's Low
$43.48
Volume
101,094
Avg. Vol
37,078
52-wk High
$44.27
52-wk Low
$29.29

HITK.OQ

Chart for HITK.OQ

About

Hi-Tech Pharmacal Co., Inc. is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states,... (more)

Overall

Beta: 0.92
Market Cap (Mil.): $602.73
Shares Outstanding (Mil.): 13.91
Dividend: 1.50
Yield (%): --

Financials

  HITK.OQ Industry Sector
P/E (TTM): 65.43 32.69 32.79
EPS (TTM): 0.66 -- --
ROI: 3.58 19.77 19.03
ROE: 3.65 20.48 19.80
Search Stocks

Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions

WASHINGTON - Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.

14 Apr 2014

UPDATE 1-Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions

WASHINGTON, April 14 - Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.

14 Apr 2014

Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions

WASHINGTON, April 14 - Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.

14 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Validea
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks